Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen Debuts Oncology Biosimilars Bevacizumab And Trastuzumab In US

Jul 19 2019

• By David Wallace

Amgen — Amgen has launched two US biosimilars • Source: Shutterstock

Related Content

Pfizer Could Launch US Bevacizumab This Year Despite Patent Thicket

Jul 01 2019

FDA Approves Amgen And Allergan’s Kanjinti Trastuzumab Biosimilar

Jun 14 2019

Biosimilar Litigation Settlement Score Card: Genentech-Pfizer Herceptin Agreement Is 10th Deal

Dec 09 2018

Related Companies

Amgen, Inc.

Genentech, Inc.

Viatris Inc.

Biocon, Ltd.

Pfizer Inc.

Roche Holding AG

Samsung Bioepis Co., Ltd.

Allergan plc

Additional Topics

United States Strategy Biosimilars Intellectual Property BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.